...
首页> 外文期刊>EFSA Journal >Scientific Opinion on the modification of the authorisation of a health claim related to plant sterol esters and lowering blood LDL‐cholesterol; high blood LDL‐cholesterol is a risk factor in the development of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006, following a request in accordance with Article 19 of Regulation (EC) No 1924/2006
【24h】

Scientific Opinion on the modification of the authorisation of a health claim related to plant sterol esters and lowering blood LDL‐cholesterol; high blood LDL‐cholesterol is a risk factor in the development of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006, following a request in accordance with Article 19 of Regulation (EC) No 1924/2006

机译:关于修改与植物固醇酯和降低血液中低密度脂蛋白胆固醇有关的健康声明授权的科学意见;依照(EC)1924/2006号法规第19条的要求,根据(EC)1924/2006号法规第14条,高血LDL-胆固醇是导致(冠状动脉)心脏病发展的危险因素

获取原文
           

摘要

Following an application from SANOFI‐AVENTIS FRANCE, submitted pursuant to Article 19 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the modification of the authorisation of a health claim related to plant sterol esters and lowering blood LDL‐cholesterol (high blood LDL‐cholesterol is a risk factor in the development of (coronary) heart disease), pursuant to Article 14 of Regulation (EC) No 1924/2006. The applicant requested an extension of the conditions of use to powder supplements to be diluted in water at a dose of 2 g per day, which would lower blood LDL‐cholesterol concentrations by “5.4‐8.1 %” after six weeks of daily consumption. Plant sterol esters are sufficiently characterised. Lowering blood LDL‐cholesterol concentrations is a beneficial physiological effect and elevated blood LDL‐cholesterol concentration is a risk factor for coronary heart disease. The target population is subjects who need and want to lower their blood cholesterol. In weighing the evidence, the Panel took into account that only one human intervention study showed a reduction in blood LDL‐cholesterol concentrations after six weeks of consuming 2 g/day of plant sterol esters in powder, the large uncertainty surrounding the estimates of this effect, and that the results of that study have not been replicated in other studies. The Panel reiterates its previous conclusion that, while plant sterols added to foods such as margarine‐type spreads, mayonnaise, salad dressings, and dairy products have been shown consistently to lower blood LDL‐cholesterol concentrations in a large number of studies, the effective dose of plant sterols (as powder diluted in water) needed to achieve a given magnitude of effect in a given timeframe cannot be established with the data provided.
机译:在法国SANOFI-AVENTIS公司根据法规(EC)1924/2006第19条通过法国主管部门提交的申请后,要求EFSA营养产品,营养和过敏问题专家组(NDA)对根据法规(EC)第14条,修改与植物甾醇酯有关的健康声明授权并降低血液中LDL-胆固醇(高血LDL-胆固醇是发展(冠状动脉性心脏病)的危险因素)第1924/2006号。申请人要求将使用条件延长至每天以2 g的水稀释的粉状补充剂,这将使每日食用六周后的血液LDL-胆固醇浓度降低“ 5.4-8.1%”。植物固醇酯具有足够的特征。降低血液中的LDL-胆固醇浓度是有益的生理作用,而血液中的LDL-胆固醇浓度升高是冠心病的危险因素。目标人群是需要和想要降低其血液胆固醇的对象。在权衡证据时,专家小组考虑到只有一项人体干预研究显示,每天服用2 g /天植物粉末固醇酯六周后,血液中LDL-胆固醇的浓度降低,这种影响的估计存在很大不确定性,并且该研究的结果未在其他研究中重复。专家小组重申其先前的结论,即尽管在许多研究中已证明,添加到人造黄油,蛋黄酱,色拉调料和乳制品等食品中的植物固醇能够持续降低血液中的LDL-胆固醇浓度,但有效剂量在提供的数据中,无法确定在给定的时间内达到给定效果的植物甾醇(以水稀释粉末形式)的数量。

著录项

  • 来源
    《EFSA Journal》 |2014年第2期|共14页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种
  • 中图分类 食品工业;
  • 关键词

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号